Non classé
EuropaColon Slovenia Celebrates Its 15th Anniversary
This March EuropaColon Slovenia rang in its 15th anniversary as a patient association! EC Slovenia was an original member of EuropaColon, the Europ...
Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers
At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...
Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours
Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the...
The First International Management Guidelines for Early-Onset Colorectal Cancer
This March, the Clinical Gastroenterology and Hepatology journal published the first management guidelines for Early-Onset Colorectal Cancer (eo-CR...
Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer
The combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) immunotherapies has been approved by the European Commission (EC) for the first-l...
Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma
The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the f...
European Commission Gathered Evidence on Vaccine-preventable Cancers
Earlier this month, DiCE responded to the call for evidence by the EU Commission. DiCE highlighted that to mitigate the rising incidence of Liver ...
16 February is World Cholangiocarcinoma Day
DiCE is proud to support GCCA’s international effort to raise much-needed awareness of CCA, devastating cancer that occurs in the bile ducts in o...
First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer
On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first...
Trastuzumab Deruxtecan Approved as Second-line Treatment in Europe For Patients With HER2-positive Advanced Gastric Cancer
On December 19th the European Commission (EC) approved the use of trastuzumab deruxtecan (Enhertu ®) plus chemotherapy (gemcitabine plus cisplatin...